Clinical trials in Lyon – page 79

1 204 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Lyon at a glance

1 204

clinical trials

Research sites7

Quick filters

1 204 trials in Lyon

Open in trial search

Chronic cutaneous lupus erythematosus+2

Not recruiting

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational

France

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

HER2 positive breast cancer

Not recruiting

Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

Registered drugNo placebo

Study of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug

France

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Giant cell arteritis

Not recruiting

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo

Comparing Methotrexate and Tocilizumab for Treating Giant Cell Arteritis in Patients: A Study on Effectiveness and Safety

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Folic Acid
Sponsor:Centre Hospitalier Universitaire De Dijon

Contact Research Centre

Neoplasm malignant+1

Not recruiting

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo

Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Canakinumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Comparing drug combinations with panitumumab for patients with RAS and B-RAF wild-type metastatic colorectal cancer

Registered drugNo placebo

Comparing drug combinations with panitumumab for patients with RAS and B-RAF wild-type metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Levofolinate
Sponsor:Unicancer

Contact Research Centre

Non-small cell lung cancer+3

Not recruiting

Study on Chemotherapy with Paclitaxel, Cisplatin, and Carboplatin for Patients with Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on Chemotherapy with Paclitaxel, Cisplatin, and Carboplatin for Patients with Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Contact Research Centre

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Janssen Cilag International

Contact Research Centre

Hormone receptor positive breast cancer+2

Not recruiting

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo

Study of palbociclib with hormone therapy versus hormone therapy alone in patients with recurrent hormone receptor-positive/HER2-negative breast cancer after surgery

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Palbociclib
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Acute myeloid leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Quizartinib Dihydrochloride
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cetrelimab
Sponsor:Janssen Cilag International

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

Triple-negative breast cancer treatments
Gastric and esophageal cancer therapies
Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

Novel COVID-19 intranasal vaccine development
Yellow fever vaccine studies
ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

Chronic kidney disease management
Heart failure prevention
Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Back to France All countries